The decrease in surface antigen from 9000 U/ml to 7000 U/ml with interferon is a tendency to improve. Surface antigen 9000 U/ml is antigen-positive and may be a carrier of hepatitis B virus or may be in the active stage of hepatitis B. After interferon treatment, the patient’s viral load decreases to 7000 U/ml of surface antigen, which is a tendency of improvement, but still belongs to the high phenomenon, and further treatment is needed. Hepatitis B surface antigen is one of the signs of hepatitis B virus infection, usually the titer of hepatitis B surface antigen is positively correlated with the hepatitis B viral load, the higher the titer of hepatitis B surface antigen, the higher the hepatitis B viral load. Adverse reactions to interferon can include nausea, vomiting, lack of appetite, drowsiness, arthralgia, and headache, as well as mild alopecia, and redness and swelling of the skin with topical use. If the diagnosis of hepatitis B is confirmed, it is recommended to seek prompt medical attention and standardized treatment under the guidance of a medical professional in order to reduce the adverse effects of the disease.